Skip to contentD
DNA X, Inc.
D
SONMDNA X, Inc. Q3 2025 · 10-Q
Revenue$16.21M$16.21M+7.9% vs Q3 2024 Net Income-$4.75M-$4.75MN/M vs Q3 2024 EPS Diluted-$4.83-$4.83N/M vs Q3 2024 Gross Profit$1,816,000−57.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
DNA X, Inc. · CIK 1178697 · Engraved from SEC EDGAR
Operating Cash Flowderived-$7,034,000N/M Margins · derivedGross margin11.2%−17.0 pt vs Q3 2024
Operating margin-24.5%−8.7 pt vs Q3 2024
Net margin-29.3%−12.6 pt vs Q3 2024
ended Sep 30, 2025 · filed Oct 31, 2025 · 31 d after period end